🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 15 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 27/05/1992 | 5,00 | 5,25 | 4,88 | 5,06 | +1,25% | 7,50% | 38.600 |
| 26/05/1992 | 5,25 | 5,25 | 5,00 | 5,00 | -4,76% | 4,76% | 17.800 |
| 22/05/1992 | 5,25 | 5,25 | 5,00 | 5,25 | +0,00% | 4,76% | 8.400 |
| 21/05/1992 | 5,00 | 5,25 | 5,00 | 5,25 | +0,00% | 5,00% | 8.600 |
| 20/05/1992 | 5,25 | 5,25 | 5,00 | 5,25 | +5,00% | 4,76% | 3.200 |
| 19/05/1992 | 5,13 | 5,38 | 4,88 | 5,00 | -4,76% | 9,76% | 811.600 |
| 18/05/1992 | 5,13 | 5,38 | 5,13 | 5,25 | +2,44% | 4,88% | 22.800 |
| 15/05/1992 | 5,50 | 5,63 | 5,13 | 5,13 | -6,82% | 9,09% | 90.400 |
| 14/05/1992 | 5,75 | 5,75 | 5,50 | 5,50 | +0,00% | 4,35% | 7.000 |
| 13/05/1992 | 5,63 | 5,75 | 5,50 | 5,50 | -2,22% | 4,44% | 132.400 |
| 12/05/1992 | 6,00 | 6,00 | 5,63 | 5,63 | -4,26% | 6,25% | 97.200 |
| 11/05/1992 | 5,63 | 6,00 | 5,63 | 5,88 | +3,30% | 6,67% | 8.200 |
| 08/05/1992 | 5,69 | 5,69 | 5,69 | 5,69 | +0,00% | 0,00% | 0 |
| 07/05/1992 | 6,00 | 6,00 | 5,69 | 5,69 | -2,15% | 5,21% | 204.200 |
| 06/05/1992 | 6,00 | 6,00 | 5,75 | 5,81 | -1,06% | 4,17% | 90.800 |
| 05/05/1992 | 6,00 | 6,00 | 5,63 | 5,88 | +4,44% | 6,25% | 15.000 |
| 04/05/1992 | 6,00 | 6,00 | 5,63 | 5,63 | -3,23% | 6,25% | 800 |
| 01/05/1992 | 5,88 | 6,00 | 5,63 | 5,81 | -1,06% | 6,38% | 6.800 |
| 30/04/1992 | 5,88 | 6,00 | 5,63 | 5,88 | +4,44% | 6,38% | 13.400 |
| 29/04/1992 | 5,63 | 5,88 | 5,63 | 5,63 | +0,00% | 4,44% | 20.400 |
| 28/04/1992 | 6,00 | 6,00 | 5,63 | 5,63 | -6,25% | 6,25% | 49.600 |
| 27/04/1992 | 5,75 | 6,00 | 5,75 | 6,00 | +4,35% | 4,35% | 50.600 |
| 24/04/1992 | 6,13 | 6,13 | 5,75 | 5,75 | -2,13% | 6,12% | 10.200 |
| 23/04/1992 | 5,88 | 6,13 | 5,88 | 5,88 | +2,17% | 4,26% | 359.800 |
| 22/04/1992 | 5,88 | 6,13 | 5,75 | 5,75 | -4,17% | 6,38% | 230.600 |
| 21/04/1992 | 6,13 | 6,13 | 5,75 | 6,00 | +4,35% | 6,12% | 128.000 |
| 20/04/1992 | 5,75 | 6,13 | 5,75 | 5,75 | -4,17% | 6,52% | 135.600 |
| 16/04/1992 | 5,75 | 6,13 | 5,75 | 6,00 | +0,00% | 6,52% | 89.800 |
| 15/04/1992 | 6,00 | 6,00 | 5,63 | 6,00 | +6,67% | 6,25% | 62.000 |
| 14/04/1992 | 6,00 | 6,00 | 5,63 | 5,63 | -3,23% | 6,25% | 34.800 |